Zacks Investment Research upgraded shares of Aileron Therapeutics (NASDAQ:ALRN) from a sell rating to a hold rating in a report issued on Wednesday, January 10th.
According to Zacks, “Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in developing and commercializing a novel class of therapeutics primarily in the United States. The companys lead product includes ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers which are in clinical stage. Aileron Therapeutics, Inc. is based in Cambridge, Massachusetts. “
Shares of Aileron Therapeutics (ALRN) opened at $8.52 on Wednesday. Aileron Therapeutics has a one year low of $8.50 and a one year high of $15.48.
Aileron Therapeutics (NASDAQ:ALRN) last released its quarterly earnings results on Thursday, November 9th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.07). equities analysts predict that Aileron Therapeutics will post -1.76 EPS for the current year.
In other Aileron Therapeutics news, major shareholder Apple Tree Partners Ii Lp sold 150,000 shares of Aileron Therapeutics stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $9.80, for a total transaction of $1,470,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System purchased a new stake in Aileron Therapeutics in the 3rd quarter valued at approximately $110,000. Tudor Investment Corp ET AL purchased a new stake in Aileron Therapeutics in the 2nd quarter valued at approximately $112,000. Vanguard Group Inc. purchased a new stake in Aileron Therapeutics in the 2nd quarter valued at approximately $111,000. Bank of New York Mellon Corp acquired a new position in Aileron Therapeutics in the 3rd quarter valued at $135,000. Finally, Schwab Charles Investment Management Inc. acquired a new position in Aileron Therapeutics in the 3rd quarter valued at $165,000. Institutional investors own 7.57% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Aileron Therapeutics (ALRN) Upgraded at Zacks Investment Research” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/06/aileron-therapeutics-alrn-upgraded-to-hold-by-zacks-investment-research.html.
Aileron Therapeutics Company Profile
Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.
Get a free copy of the Zacks research report on Aileron Therapeutics (ALRN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.